Immunotherapy Use in Patients With Lung Cancer and Comorbidities

Increasing Understanding about the Role Biosimilar Agents Play in Everyday Practice: A Q&A with Dr. Gary Lyman (Part 2 of 2)

Ensuring Quality of Life During Lung Cancer Survivorship Requires a Multidisciplinary Team

COVID-19 and Lung Cancer: A Call for Immediate Action

A Clinical Trial of PD-L1 Inhibitor Durvalumab and PARP Inhibitor Olaparib for Patients With EGFR-Mutated Transformed SCLC

Mutation or Amplification: Who MET the Expectations?

Large LDCT Lung Cancer Screening Program Suggests Screening Benefits Far Outweigh the Risks

Possible Benefits of Metformin for Lung Cancer Still Unknown

RET Therapy for NSCLC, a New Generation of Inhibitors

Tyrosine kinase inhibitors (TKI) or monoclonal antibodies (mAb) for the Treatment of NRG1 and, Potentially, NRG2 Fusion–Positive Malignancies

Vemurafenib Alone and Combination for Lung Cancer: A Conversation with Marcelo V. Negrao, MD

Premonitions About Lung Cancer for the Next Decade